Actively Recruiting
Evaluating Treatable Traits Across the Spectrum of Chronic Obstructive Airways Disease
Led by University of Leeds · Updated on 2025-03-30
100
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
Sponsors
U
University of Leeds
Lead Sponsor
T
The Leeds Teaching Hospitals NHS Trust
Collaborating Sponsor
AI-Summary
What this Trial Is About
Respiratory disease affects one in five people and is a leading cause of global morbidity and mortality. Chronic obstructive airways diseases encompass conditions characterised by expiratory airflow limitation, exertional dyspnoea, activity limitation and impaired quality of life. The most common conditions include chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, cystic fibrosis and primary ciliary dyskinesia. In recent years, there has been concerted effort in the scientific and respiratory medicine community to improve the diagnosis and management of chronic obstructive airways diseases using personalised or precision medicine (i.e., tailoring therapies and interventions according to specific "treatable traits") and identifying phenotypes or endotypes using validated biomarkers. To date, however, research in this setting has primarily focussed on people with COPD and asthma, with limited studies in other forms of chronic obstructive airways diseases. The aim of this study is therefore two-fold; first, to compare pulmonary physiology (i.e., large and small airway involvement) and extra-pulmonary manifestations across the spectrum of chronic obstructive airways, and second, to determine how disease-specific treatable traits associate with physical activity and health-related quality of life.
CONDITIONS
Official Title
Evaluating Treatable Traits Across the Spectrum of Chronic Obstructive Airways Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Prior diagnosis of airways disease in accordance with European Respiratory Society guidelines
- Non-smokers or ex-smokers (pack history recorded)
- Male or female aged 18 to 65 years
- Ability to provide written informed consent
- Full understanding of spoken and written English
- Cystic fibrosis patients on triple CFTR modulators (90% of cohort)
- Cystic fibrosis patients not on CFTR modulators
- Healthy controls with no respiratory symptoms, no inhaler use, and no history of respiratory disease
You will not qualify if you...
- Severe exacerbation requiring hospital admission or oral corticosteroids in the past two months
- Contraindications to cardio-pulmonary exercise testing or submaximal exercise testing
- Contraindications to pulmonary function testing
- Contraindications to dual energy x-ray (DEXA) scanning, including pregnancy, recent contrast media use, or subject weight
- Non-ambulant or musculoskeletal impairments affecting daily activities or exercise testing
- Significant cognitive impairment preventing consent or safe test performance
- Currently receiving oxygen therapy
- Unable to provide consent
- Infection with Burkholderia Cepacia Complex, mycobacterium tuberculosis, or mycobacterium abscessus
- Lung transplantation
- Diagnosis of cardiovascular disease
- Abnormal blood tests such as anemia or moderate/severe renal failure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Leeds
Leeds, Leeds, United Kingdom, LS2 9JT
Actively Recruiting
Research Team
O
Oliver Price, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here